Replies to post #706 on RedHill Biopharma Ltd (RDHL)

[Amatuer17]

It is amazing that this co executes consistently but do not get visibility and mc is still 170 million

[H2R]

Hi MidasTouch,

This part of the PR highlights how well they keep on executing:

Top-line results from the Phase III study with BEKINDA® 24 mg for acute gastroenteritis and gastritis (the GUARD study) are expected in the second quarter of 2017. In February 2017, RedHill announced that the last patient had completed the treatment course and observation period in the randomized, double-blind, placebo-controlled GUARD study, which treated 320 adults and children over the age of 12 in 29 U.S. clinical sites.

They keep moving along nicely. If positive, the top line results will help with credibility and valuation IMHO.